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Abstract: Objective: To discuss the prevention and treatment of HJJB (salidroside, curcumin, gypenoside and 
atractylodes macrocephala polysaccharide) compound on non-alcoholic steatohepatitisin rats induced by high-fat diet. Methods: 
Non-alcoholic steatohepatitis model was induced by high-fat diet for 14 weeks. From the ninth week, the rats were randomly 
divided into model group, HJJB high-dose group, HJJB low-dose group and rosiglitazone group, and were given gavage for six 
weeks. The observing items including: pathological changes of liver tissue (HE staining); the changesof contents of liver tissue 
triglyceride (TG) and free fatty acid (FFA); the activities of serum alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), glutamyl transpeptidase (GGT) and contents of serum total cholesterol (TC) and TG. Results: Significant hepatocellular 
steatosis and vacuolar degeneration were observed inthe liver tissue of the model group. The contents of TG and FFA in liver 
tissue of model group were significantly higher than those of normal group (P<0.01), and the activities of serum ALT, AST, GGT 
and the contents of TG and TC of model group were higher than those of normal group too (P<0.01). Hepatic pathological changes 
in the HJJB compound high-dose, low-dose groups were all significantly meliorated. The levels of liver TG, FFA and serum ALT, 
AST, GGT, TG and TC of HJJB high-dose group, HJJB low-dose group were significantly lower than that of model group (P<0.01). 
In addition, the contents of liver TG and FFA and serum ALT, AST, GGT of HJJB compound high-dose group were lower than 
those of HJJB compound low-dose and rosiglitazone group (P<0.05, P<0.01). Conclusion: HJJB compound does well in the 
prevention and treatment of non-alcoholic steatohepatitis induced by high-fat diet.
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组别 体质量（g） 肝湿重（g） 肝指数（%）
正常组 536.88±59.66 13.43±1.89 2.53±0.47
模型组 657.75±47.34** 25.36±6.09** 3.88±1.05**
HJJB方高剂量组 579.88±63.92△△ 14.47±2.61△△  2.51±0.44△△
HJJB方低剂量组 563.25±43.31△△ 15.94±1.91△△ 2.86±0.44△△
























HJJB方高剂量组 1.39±0.19△△   4.74±0.28△△
HJJB方低剂量组 1.63±0.38△△   5.10±0.80△△








组别 ALT AST GGT
正常组 20.94±7.49 21.20±6.95 60.09±6.09
模型组 58.55±13.45** 52.15±14.10** 120.72±16.61**
HJJB方高剂量组 28.48±5.93△△ 25.53±4.41△△ 71.51±12.21△△
HJJB方低剂量组 42.31±9.66△△▲▲ 35.94±10.48△△▲ 90.20±5.27△△▲▲










F0 F1 F2 F3 F4
正常组 8 - - - - 8
模型组** - - 0 5 3 8
HJJB方高剂量组△△ - 3 3 2 - 8
HJJB方低剂量组△△ - 1 3 4 0 8
罗格列酮组△▲ - - 3 4 1 8
合计 8 4 9 15 4 40
Ridit值 0.1000 0.2500 0.4125 0.7125 0.9500 -
图1 各组大鼠肝组织脂肪变性示意图（HE×200）
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